Lenovo to Be Main Sponsor of Red Bull Illume Image Quest 2021
25.2.2021 17:00:00 EET | Business Wire | Press release
The world’s greatest adventure and action sports imagery contest, Red Bull Illume® returns in 2021 with global technology leader, Lenovo™, as its Exclusive Computing Sponsor. A showcase for the best of adventure and action sports imagery, the competition is expected once again to receive tens of thousands of entries from around the world including some of the most creative and extreme images ever captured. As part of this two-year partnership, Lenovo will be involved through brand, product placement and logo incorporation for both online and in-person content, prizes for finalists and winners, as well as having promotional access to the incredible contest imagery.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210225005071/en/
Austrian photographer Philip Platzer gets the perfect in-air shot of Red Bull Skydive teammate, Marco Fürst, participating in The Megaswing Project. (Photo: Philip Platzer/ Red Bull Illume)
Lenovo enables a more inclusive and inspired world for all through smarter technology, so it’s fitting Lenovo should present this year’s Best of Instagram category that opens up the competition to all. Unlike the contest’s nine other categories which are adjudicated by a panel of 50 photo and digital experts from around the world, the finalists and category winners for Best of Instagram by Lenovo are selected through public voting. Each month, from March 1 to July 31, 2021, there will be five still and five moving images pre-selected by an internal jury which are put out to a community vote. The top choices from each month will become official Red Bull Illume Image Quest 2021 Finalists; from these, a final online vote will decide the best still image and the best moving image, to be crowned as Lenovo’s Best of Instagram Category Winners. Anyone can submit their moving or still images on Instagram by tagging @redbullillume and #rbi21submission.
The Overall Winner of Red Bull Illume Image Quest 2021 is selected from all the category winners by the international judging panel. There is a total of 10 categories which are created to truly shine a light on the lifestyle and culture behind today’s professional and amateur content creators and their dedication to the craft. Each edition of the contest brings out a new level of never-seen-before creativity, and this edition is bound to be full of imagery that pushes the boundaries of content creation in adventure and action sports imagery.
Along with receiving well-earned career exposure as an official Red Bull Illume winner, their work will tour the globe, illuminated on huge lightboxes. The winners are also awarded prize packages that include trophies and the latest Lenovo products to power even more creative self-expression. Their work will be included in the official Red Bull Illume photobook and showcased during the winner award ceremony planned for November 2021 and attended by Ulrich Grill, the founder of the Red Bull Illume Image Quest.
“Lenovo is proud to support the sixth edition of Red Bull Illume Image Quest that brings together photographers and content creators whose bold work continually inspires us,” said Matt Bereda, Vice President of Global Consumer Marketing, PCs and Smart Devices, Lenovo. “We see many of our consumer PC, smart home, and tablet customers are passionate hobbyists. They enjoy photography and digital storytelling, and not all of them are paid professionals—they just love capturing and enhancing imagery to share with others and hang on their walls. If this new normal has taught us anything about our world and ourselves, it’s that we’re resilient, our technology is adaptable, and that making meaningful connections with others through shared creative pursuits are the bright spots in life that really matter.”
“Red Bull Illume is like the Oscars of adventure and action sports imagery and we are extremely proud to have Lenovo join the 2021 edition,” said Ulrich Grill, Founder of Red Bull Illume. “This contest honors the creativity and hard work that goes into producing one-of-a-kind imagery and Lenovo gives content creators the tools they need to express their unique ideas.”
A shared dedication to transformative experiences and using innovative technology to push boundaries makes Red Bull Illume and Lenovo ideal partners. Meaningful innovation is essential to advancing photo technologies and solidifying image capture as an artform. Similarly, Lenovo innovation provides digital creators with better photo management and enhancement experiences and smarter technology so they can build bigger for a more creative world – making consumer products, services, and software solutions more attuned to the unique needs of modern content creators.
The contest is open for submissions from March 1 to July 31, 2021. It is free for anyone to enter and voting is open to all on redbullillume.com. To view previous winning images, check out the gallery, here.
About Lenovo
Lenovo (HKSE: 992) (ADR: LNVGY) is a US$50 billion Fortune Global 500 company, with 63,000 employees and operating in 180 markets around the world. Focused on a bold vision to deliver smarter technology for all, we are developing world-changing technologies that create a more inclusive, trustworthy and sustainable digital society. By designing, engineering and building the world’s most complete portfolio of smart devices and infrastructure, we are also leading an Intelligent Transformation – to create better experiences and opportunities for millions of customers around the world. To find out more visit https://www.lenovo.com, follow us on LinkedIn, Facebook, Twitter, YouTube, Instagram, Weibo and read about the latest news via our StoryHub.
About Red Bull Illume
The Image Quest 2021 is the sixth edition bringing together the amazing work of photographers and content creators from around the world. In 2019, a record-breaking 59,551 images were submitted by thousands of creators from countries all around the world. Submissions for the contest will take place from March 1 to July 31, 2021 and can be entered on redbullillume.com and on Instagram. A judging panel of 50 photo editors and digital experts will select the Finalists, Category Winners and an Overall Winner, to be unveiled at the Winner Award Ceremony in November 2021. Follow us on Instagram, Facebook, Twitter, YouTube and Pinterest.
LENOVO is a trademark of Lenovo. RED BULL ILLUME is a trademark of Red Bull GmbH. Instagram is a trademark of Instagram, LLC. All other trademarks are the property of their respective owners. ©2021, Lenovo Group Limited.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210225005071/en/
Contact information
Wendy Fung
wfung@zenogroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom